Abstract
Introduction: Recent studies have indicated that a proportion of patients with renal failure, left ventricular hypertrophy, or cryptogenic stroke have sequence variants in their aGal A gene (Fabry disease), which has resulted in an increase in diagnostic activities for this disorder. The diagnostic process for lysosomal storage disorders may result in findings of unknown clinical significance. Here we report such an unexpected outcome.
Case: A 32-year-old male presented at the emergency department because of a transient ischemic attack. Extensive investigations revealed no cause and an initial diagnosis of cryptogenic stroke was made. Subsequently, aGal A activity was measured in a bloodspot and was shown to be normal, but the activity of alpha-l-iduronidase (IDUA), used as reference enzyme, was unexpectedly low: 0.5 umol/L (ref = 1.7–14.3). A diagnosis of IDUA deficiency, mucopolysaccharidosis type 1S or Scheie disease was considered. IDUA gene analysis revealed two homozygous sequence alterations: a silent sequence change (979C > T) in exon 7 (N297N) and an unknown missense mutation 875A > T (R263W). Physical examination was completely normal, without clinical signs of mucopolysaccharidosis type I (MPS I). Leukocyte IDUA activity was also low: 2.1 nmol/mg prot/h (ref = 14–40 nmol prot/h), but higher than the patient range of <0.1 nmol/mg prot/h. Urinary glycosaminoglycan levels were normal both quantitatively and qualitatively. It was concluded that there was low IDUA activity without clinical symptoms and the diagnosis of mucopolysaccharidosis I was discarded.
Conclusion: The diagnostic process for lysosomal storage disorders may result in biochemical abnormalities of unknown clinical significance. Early evaluation by a specialist in inborn errors of metabolism may help to avoid anxiety in patients and unnecessary additional analyses.
Competing interests: None declared
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aronovich EL, Pan D, Whitley CB (1996) Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet 58:75–85
Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195–196
Couzin-Frankel J (2011) Human genome 10th anniversary. What would you do? Science 331:662–665
Ding A, Eisenberg JD, Pandharipande PV (2011) The economic burden of incidentally detected findings. Radiol Clin North Am 49:257–265
Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307–314
Fujii D, Manabe Y, Tanaka T, Kono S, Sakai Y, Narai H, Omori N, Furujyo M, Abe K (2012) Scheie syndrome diagnosed after cerebral infarction. J Stroke Cerebrovasc Dis 21:330–332
Gal A, Hughes DA, Winchester B (2011) Toward a consensus in the laboratory diagnostics of Fabry disease – recommendations of a European expert group. J Inherit Metab Dis 34:509–514
Kelly AS, Metzig AM, Steinberger J, Braunlin EA (2012) Endothelial function in children and adolescents with mucopolysaccharidosis. J Inherit Metab Dis.
Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease–a comprehensive review of the medical literature. Genet Med 12:668–679
Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE (2005) Mucopolysaccharidosis I under enzyme replacement therapy with laronidase–a mortality case with autopsy report. J Inherit Metab Dis 28:1146–1148
Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217–222
Lyons JA, Dickson PI, Wall JS, Passage MB, Ellinwood NM, Kakkis ED, McEntee MF (2011) Arterial pathology in canine mucopolysaccharidosis-I and response to therapy. Lab Invest 91:665–674
Neufeld EF, Muenzer J (2007) The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A (eds) The online metabolic and molecular bases of inherited disease. McGraw-Hill, New York
Nishimoto J, Inui K, Okada S, Ishigami W, Hirota S, Yamano T, Yabuuchi H (1988) A family with pseudodeficiency of acid alpha-glucosidase. Clin Genet 33:254–261
Sijmons RH, Van Langen IM, Sijmons JG (2011) A clinical perspective on ethical issues in genetic testing. Account Res 18:148–162
Soultati A, Alexopoulou A, Dourakis SP, Dimopoulou H, Katsaounis P, Cokkinos D, Archimandritis AJ (2010) The burden of incidental findings in clinical practice in a tertiary care center. Eur J Intern Med 21:123–126
Stern RG (2012) The incidental solitary pulmonary nodule: algorithms, options, and patient choice. Am J Med 125:221–222
Triggs-Raine BL, Mules EH, Kaback MM, Lim-Steele JS, Dowling CE, Akerman BR, Natowicz MR, Grebner EE, Navon R, Welch JP (1992) A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening. Am J Hum Genet 51:793–801
Wang RY, Covault KK, Halcrow EM, Gardner AJ, Cao X, Newcomb RL, Dauben RD, Chang AC (2011) Carotid intima-media thickness is increased in patients with mucopolysaccharidoses. Mol Genet Metab 104:592–596
Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Verena Peters
Synopsis
Synopsis
Interpretation of diagnostic tests for rare diseases by clinical experts is vital.
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Langereis, E.J. et al. (2012). Considering Fabry, but Diagnosing MPS I: Difficulties in the Diagnostic Process. In: Zschocke, J., Gibson, K.M., Brown, G., Morava, E., Peters, V. (eds) JIMD Reports – Case and Research Reports, 2012/6. JIMD Reports, vol 9. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2012_189
Download citation
DOI: https://doi.org/10.1007/8904_2012_189
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35517-2
Online ISBN: 978-3-642-35518-9
eBook Packages: MedicineMedicine (R0)